Drugs / DX-104
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07395739 | Mar 2026 → May 2027 expected | meningococcemia | Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DX-104 | “Participants in this arm will receive three doses of DX-104 at Months 0, 1, and 6.” NCT07395739 ↗ |
| Known as | Group B Meningococcal OMV Vaccine | “Group B Meningococcal OMV Vaccine (DX-104)” NCT07395739 ↗ |